Hla-deleted glomerular endothelial cells and diagnostic method

The invention relates to an engineered glomerular endothelial cell comprising areduction in expression of a human leukocyte antigen and its use in an […]

Nanobody targeting von wilebrand factor a3-domain

"Inventors have isolated a single-domain antibody (designated KB-VWF-D3.1) targeting the A3-domain, the epitope of which overlaps the collagen-binding […]

Methods for predicting the survival time of patients suffering from a

The present invention relates to methods for predicting the survival time of patients suffering from a lung cancer. In particular, the present […]

Methods and kits for the simultaneous detection of autoantibodies

The inventors developed a multiplex test for the detection of autoantibodies directed against five DEJ proteins (NC16A and C-terminal domain of BP180, […]

Method for predicting the response to a bipolar disorder treatment

The invention relates to the field of Bipolar Disorder. In a recent study, the inventors performed the first genome-wide analysis of DNA methylation […]

Method to predict the risk of a cardiovascular event in a patient with

The present invention relates to cardiovascular event in a patient with type 2 diabetes. In a cross-sectional study population of 672 participants […]

Use of soluble cd95l as a prognostic marker in

PTLDs arise after solid organ and hematopoietic stem cell transplants, with occurrences linked to immunosuppressive therapy and EBV status. Initial […]

Method to predict the risk of a cardiovascular event in a patient

The inventors have identified new peptide biomarkers related to methylglyoxal (MGO)- induced glycation of plasma albumin, as well as the most abundant […]

Methods of predicting the risk of recurrence and/or death of patients

Circulating tumor DNA (ctDNA) is a promising non-invasive biomarker in cancer. The inventors aim to assess the dynamic evolution of ctDNA in patients […]

Use of ykl-40 as a biomarker for assessing functional outcome in acute

Today, more than 40% of acute ischemic stroke (AIS) patients treated with endovascular therapy (EVT) will remain severely disabled at 3 months. The […]